Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
[HTML][HTML] Insights for COVID-19 in 2023
FJM Sánchez, M Martínez-Sellés… - Revista Española de …, 2023 - ncbi.nlm.nih.gov
Predictions for a near end of the pandemic by the World Health Organization should be
interpreted with caution. Current evidence indicates that the efficacy of a fourth dose of …
interpreted with caution. Current evidence indicates that the efficacy of a fourth dose of …
The association of baseline plasma SARS-CoV-2 nucleocapsid antigen level and outcomes in patients hospitalized with COVID-19
ACTIV-3/TICO Study Group - Annals of internal medicine, 2022 - acpjournals.org
Background: Levels of plasma SARS-CoV-2 nucleocapsid (N) antigen may be an important
biomarker in patients with COVID-19 and enhance our understanding of the pathogenesis of …
biomarker in patients with COVID-19 and enhance our understanding of the pathogenesis of …
Update on Remdesivir in the Treatment of Novel Coronavirus Pneumonia
H Feng, KV Lakshmi, CT Ng… - … In Microbes & …, 2023 - journals.hh-publisher.com
Worldwide epidemic prevention and control remain under significant stress due to the global
novel coronavirus disease 2019 (COVID-19) pandemic and the ongoing emergence of …
novel coronavirus disease 2019 (COVID-19) pandemic and the ongoing emergence of …
Physicochemical characteristics of antimicrobials and practical recommendations for intravenous administration: a systematic review
F Borgonovo, M Quici, A Gidaro, D Giustivi, D Cattaneo… - Antibiotics, 2023 - mdpi.com
Most antimicrobial drugs need an intravenous (IV) administration to achieve maximum
efficacy against target pathogens. IV administration is related to complications, such as …
efficacy against target pathogens. IV administration is related to complications, such as …
Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19
NR Aggarwal, J Nordwall, DL Braun… - Clinical Infectious …, 2024 - academic.oup.com
Background Persistent mortality in adults hospitalized due to acute COVID-19 justifies
pursuit of disease mechanisms and potential therapies. The aim was to evaluate which virus …
pursuit of disease mechanisms and potential therapies. The aim was to evaluate which virus …
One week of oral camostat versus placebo in nonhospitalized adults with mild-to-moderate Coronavirus Disease 2019: A randomized controlled phase 2 trial
N Jilg, KW Chew, MJ Giganti, ES Daar… - Clinical Infectious …, 2023 - academic.oup.com
Background Camostat inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) infection in vitro. We studied the safety and efficacy of camostat in ACTIV-2/A5401, a …
2) infection in vitro. We studied the safety and efficacy of camostat in ACTIV-2/A5401, a …
[HTML][HTML] Clinical development of antivirals against SARS-CoV-2 and its variants
Q Lan, Y Yan, G Zhang, S Xia, J Zhou, L Lu… - Current Research in …, 2023 - Elsevier
The unceasing global spread of severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) calls for the development of novel therapeutics. Although many newly developed …
CoV-2) calls for the development of novel therapeutics. Although many newly developed …
[PDF][PDF] One week of oral camostat versus placebo in nonhospitalized adults with mild-to-moderate coronavirus disease 2019 (COVID-19): a randomized controlled …
N Jilg, KW Chew, MJ Giganti, ES Daar… - Clin Infect …, 2023 - jonathanlilab.bwh.harvard.edu
Background. Camostat inhibits severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) infection in vitro. We studied the safety and efficacy of camostat in ACTIV-2/A5401, a …
CoV-2) infection in vitro. We studied the safety and efficacy of camostat in ACTIV-2/A5401, a …
An ankyrin repeat chaperone targets toxic oligomers during amyloidogenesis
A Gupta, C Lu, F Wang, TF Chou, S Shan - Protein Science, 2023 - Wiley Online Library
Numerous age‐linked diseases are rooted in protein misfolding; this has motivated the
development of small molecules and therapeutic antibodies that target the aggregation of …
development of small molecules and therapeutic antibodies that target the aggregation of …